检索结果-南通市图书馆

High density lipoprotein as a therapeutic target:Focus on its functionality

BIOCELL 2023年第11期47卷 2361-2383页

作者： LEONARDO GÓMEZ ROSSO BELÉN DAVICO EZEQUIEL LOZANO CHIAPPE WALTER TETZLAFF laura boero FERNANDO BRITES MAXIMILIANO MARTÍN School of Pharmacy and Biochemistry Laboratory of Lipids and AtherosclerosisDepartment of Clinical BiochemistryUniversity of Buenos AiresNational Scientific and Technical Research Council(CONICET)Buenos Aires1113Argentina

Cardiovascular diseases(CVDs)are the leading cause of death *** are a group of disorders of the heart and blood vessels and include coronary heart disease,cerebrovascular disease and rheumatic heart disease among other *** are multiple independent risk factors for CVD,including hypertension,age,smoking,insulin resistance,elevated low-density lipoprotein cholesterol(LDL-C)levels,and triglyceride ***-C levels have traditionally been the target for therapies aimed at reducing CVD *** density lipoprotein(HDL)constitutes the only lipoprotein fraction with atheroprotective *** HDL-targeted therapies have focused on increasing HDL-C ***,clinical trials have shown that raising HDL-C with niacin failed to achieve CVD reduction.A possible explanation for these findings is that these drugs could interfere with lipid metabolism and cause alterations in HDL structure and composition,leading to loss of *** a result,targeting HDL-C levels would be insufficient to achieve CVD risk reduction,making HDL functionality a more desirable focus for HDL-directed *** are several drugs which show the potential to improve HDL *** drugs include molecules already approved for human use,such as statins and niacin,and particularly,compounds currently undergoing development such as apolipoprotein A-I mimetics and reconstituted HDL *** therapies show promising potential to improve HDL functionality *** therapeutic strategies should incorporate HDL functionality as a main target of interest.

关键词： HDL Cholesterol efflux rHDL Apo A-I mimetics Statins Paraoxonase

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Markers of inflammation and cardiovascular disease in recently diagnosed celiac disease patients

引用

World Journal of Cardiology 2017年第5期9卷 448-456页

作者： Walter F Tetzlaff Tomás Merono Martin Menafra Maximiliano Martin Eliana Botta Maria D Matoso Patricia Sorroche Juan A De Paula laura E boero Fernando Brites Department of Clinical of Biochemistry School of Pharmacy and BiochemistryUniversity of Buenos AiresINFIBIOCCONICET Service of Gastroenterology Buenos Aires Italian Hospital Central Laboratory Buenos Aires Italian Hospital

AIM To evaluate novel risk factors and biomarkers of car-diovascular disease in celiac disease(CD) patients compared with healthy controls. METHODS Twenty adult patients with recent diagnosis of CD and 20 sex, age and body mass index-matched healthy controls were recruited during a period of 12 mo. Indicators of carbohydrate metabolism, hematological parameters and high sensitive C reactive protein were determined. Moreover, lipoprotein metabolism was also explored through evaluation of the lipid profile andthe activity of cholesteryl ester transfer protein and lipoprotein associated phospholipase A2, which is also considered a specific marker of vascular inflammation. The protocol was approved by the Ethic Committee from School of Pharmacy and Biochemistry, University of Buenos Aires and from Buenos Aires Italian Hospital, Buenos Aires, *** Regarding the indicators of insulin resistance, CD patients showed higher plasma insulin levels [7.2(5.0-11.3) m U/L vs 4.6(2.6-6.7) m U/L, P < 0.05], increased Homeostasis Model Assessment-Insulin Resistance [1.45(1.04-2.24) vs 1.00(0.51-1.45), P < 0.05] and lower Quantitative Sensitive Check index [0.33(0.28-0.40) vs 0.42(0.34-0.65), P < 0.05] indexes. Folic acid concentration [5.4(4.4-7.9) ng/m L vs 12.2(8.0-14.2) ng/m L, P < 0.01] resulted to be lower and High-sensitivity C reactive protein levels higher(4.21 ± 6.47 mg/L vs 0.98 ± 1.13 mg/L, P < 0.01) in the patient group. With respect to the lipoprotein profile, CD patients showed lower high density lipoprotein-cholesterol(HDL-C)(45 ± 15 mg/d L vs 57 ± 17 mg/d L, P < 0.05) and apo A-I(130 ± 31 mg/d L vs 155 ± 29 mg/d L, P < 0.05) levels, as well as higher total cholesterol/HDL-C [4.19(3.11-5.00) vs 3.52(2.84-4.08), P < 0.05] and apo B/apo A-I(0.75 ± 0.25 vs 0.55 ± 0.16, P < 0.05) ratios in comparison with control subjects. No statistically significant differences were detected in lipoprotein-associated lipid transfer protein and *** The presence

关键词： Inflammation Cardiovascular disease High density lipoprotein-cholesterol Lipoproteins Celiac disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：